PARIS--(BUSINESS WIRE)--Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced the initiation of a multicenter Phase I/IIa dose escalation study in Taiwan. This study will assess the safety and tolerability of repeated administration of Cytheris' investigative immunotherapy, recombinant human Interleukin-7 (CYT107), as an add-on therapy in the treatment of patients infected with genotype 1 hepatitis C (HCV) and who previously have proven non-responsive to standard treatment. The study will be conducted at four sites, two in Taipei and one each in Tainan and Kaohsiung.
